Balaji Prasad
Stock Analyst at Barclays
(2.41)
# 2,468
Out of 4,784 analysts
147
Total ratings
40.32%
Success rate
-0.04%
Average return
Main Sectors:
Stocks Rated by Balaji Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EOLS Evolus | Maintains: Overweight | $22 → $25 | $12.05 | +107.47% | 8 | Mar 5, 2025 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $10 → $11 | $8.28 | +32.85% | 5 | Mar 3, 2025 | |
| PCRX Pacira BioSciences | Maintains: Overweight | $17 → $24 | $24.91 | -3.65% | 9 | Feb 28, 2025 | |
| VTRS Viatris | Maintains: Underweight | $12 → $9 | $8.68 | +3.69% | 8 | Feb 28, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Overweight | $190 → $200 | $122.92 | +62.71% | 10 | Feb 27, 2025 | |
| ELAN Elanco Animal Health | Maintains: Overweight | $20 → $19 | $10.41 | +82.52% | 13 | Feb 26, 2025 | |
| TARS Tarsus Pharmaceuticals | Maintains: Overweight | $62 → $60 | $51.74 | +15.96% | 5 | Feb 26, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $242 → $244 | $163.11 | +49.59% | 16 | Feb 14, 2025 | |
| OGN Organon & Co. | Maintains: Overweight | $26 → $24 | $14.51 | +65.40% | 2 | Feb 14, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underweight | $20 → $22 | $21.46 | +2.52% | 8 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $481 → $520 | $415.87 | +25.04% | 9 | Feb 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $26 | $15.08 | +72.41% | 12 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $150 → $160 | $107.62 | +48.67% | 15 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $17 | $13.20 | +28.79% | 13 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $18 | $9.55 | +88.48% | 5 | Jul 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2.5 → $10 | $2.74 | +264.96% | 2 | Oct 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8 → $7 | $0.84 | +734.72% | 7 | Oct 23, 2023 |
Evolus
Mar 5, 2025
Maintains: Overweight
Price Target: $22 → $25
Current: $12.05
Upside: +107.47%
Amneal Pharmaceuticals
Mar 3, 2025
Maintains: Overweight
Price Target: $10 → $11
Current: $8.28
Upside: +32.85%
Pacira BioSciences
Feb 28, 2025
Maintains: Overweight
Price Target: $17 → $24
Current: $24.91
Upside: -3.65%
Viatris
Feb 28, 2025
Maintains: Underweight
Price Target: $12 → $9
Current: $8.68
Upside: +3.69%
Jazz Pharmaceuticals
Feb 27, 2025
Maintains: Overweight
Price Target: $190 → $200
Current: $122.92
Upside: +62.71%
Elanco Animal Health
Feb 26, 2025
Maintains: Overweight
Price Target: $20 → $19
Current: $10.41
Upside: +82.52%
Tarsus Pharmaceuticals
Feb 26, 2025
Maintains: Overweight
Price Target: $62 → $60
Current: $51.74
Upside: +15.96%
Zoetis
Feb 14, 2025
Maintains: Overweight
Price Target: $242 → $244
Current: $163.11
Upside: +49.59%
Organon & Co.
Feb 14, 2025
Maintains: Overweight
Price Target: $26 → $24
Current: $14.51
Upside: +65.40%
Phibro Animal Health
Feb 10, 2025
Maintains: Underweight
Price Target: $20 → $22
Current: $21.46
Upside: +2.52%
Feb 4, 2025
Maintains: Overweight
Price Target: $481 → $520
Current: $415.87
Upside: +25.04%
Jan 30, 2025
Maintains: Overweight
Price Target: $28 → $26
Current: $15.08
Upside: +72.41%
Dec 16, 2024
Maintains: Overweight
Price Target: $150 → $160
Current: $107.62
Upside: +48.67%
Nov 6, 2024
Maintains: Overweight
Price Target: $17 → $17
Current: $13.20
Upside: +28.79%
Jul 25, 2024
Maintains: Overweight
Price Target: $22 → $18
Current: $9.55
Upside: +88.48%
Oct 23, 2023
Maintains: Equal-Weight
Price Target: $2.5 → $10
Current: $2.74
Upside: +264.96%
Oct 23, 2023
Maintains: Overweight
Price Target: $8 → $7
Current: $0.84
Upside: +734.72%